Results 161 to 170 of about 2,234,624 (258)

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2606-2618, 15 November 2026.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau   +7 more
wiley   +1 more source

CCL5 and GLUT1 define leader cells in collective invasion of colorectal cancer

open access: yesThe Journal of Pathology, Volume 270, Issue 3, Page 288-302, November 2026.
Abstract Invasion and metastasis in multiple solid tumors are promoted by collective invasion which is organized by leader and follower cells. Yet in colorectal cancer (CRC), biomarkers and mechanisms that specify leader cells remain undefined. Here we identify biomarkers of leader cells and elucidate how they drive CRC collective invasion and ...
Zhaowen Zhang   +13 more
wiley   +1 more source

Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area (TAC/SARIFA) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis

open access: yesHistopathology, Volume 89, Issue 5, Page 835-848, November 2026.
TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam   +3 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

open access: yesInternational Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang   +10 more
wiley   +1 more source

Acidic bile salts induce APE1-dependent PRDX2 activation to drive oxaliplatin resistance via ferroptosis inhibition. [PDF]

open access: yesRedox Biol
Chen L   +13 more
europepmc   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 8, Page 2075-2083, 15 October 2026.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan   +9 more
wiley   +1 more source

GDF15 promotes 5-Fluorouracil and Oxaliplatin resistance by promoting stem cell-like phenotype in colorectal cancer. [PDF]

open access: yesBr J Cancer
Hashimoto M   +14 more
europepmc   +1 more source

Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion

open access: yesAdvanced Materials, Volume 38, Issue 56, 8 October 2026.
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy